Guggenheim lowered the firm’s price target on Acadia Healthcare (ACHC) to $27 from $29 and keeps a Buy rating on the shares following the company’s Q3 report and 2025 guidance. While the firm continues to hold a favorable view around the long-term behavioral health thesis and Acadia’s positioning, it says near-term execution “remains paramount” for greater multiple expansion.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare’s Earnings Call: Mixed Sentiments and Strategic Moves
- Optimistic Buy Rating for Acadia Healthcare Amid Strategic Growth Initiatives
- Acadia Healthcare price target lowered to $22 from $25 at Cantor Fitzgerald
- Acadia Healthcare price target lowered to $28 from $31 at UBS
- Acadia Healthcare Reports Q3 Revenue Growth Amid Challenges